A widely prescribed drug used to treat patients with chronic obstructive pulmonary disease - the fourth leading cause of death in the United States - may damage patients' hearts, according to a recent study conducted by Northwestern's Feinberg School of Medicine.
Chronic obstructive pulmonary disease, in most cases, refers to two incurable illnesses: chronic bronchitis and emphysema. Both illnesses are caused by an inflammatory response of the lungs to harmful dust or particles. Over time, the disease leads to an irreparable decline in breathing ability.
The drug in the study, ipratropium, is marketed under the brand names Atrovent and Combivent. Both drugs, called bronchodilators, manage symptoms by inhibiting mucus secretion and airway constriction.
But patients who used the ipratropium-based drugs for their COPD symptoms were 34 percent more likely to die of heart-related problems than those who used alternative medications, the Feinberg study, published Sept. 15, found.
The study was conducted by looking into the causes of death for 145,000 veterans from 1999 to 2003.
Dr. Todd Lee, lead author of the study and research assistant professor at the Institute for Healthcare Studies at Feinberg, said that even though about 12 million Americans have COPD, public knowledge about it is limited.
"COPD really flies underneath the radar screen - it's not as high-profile of a disease as cancer or heart disease," Lee said.
Although the study shows a strong correlation between ipratropium use and heart problems, researchers are still studying the actual effects of ipratropium on the cardiovascular system.
"That's a key question," Lee said. "If we knew that, the results would be more believable. We need to try to understand the systemic effects of this medication."
However, bronchodilator medication could induce increased heartbeat which might lead to potential heart ailments, he said. Lee also said the data are not completely conclusive.
2008 Woodie Awards
The DAILY encourages you to share your thoughts on this story. Please help us keep the discussion lively, but civil. Comments that are abusive to others, off-topic or vulgar, or comments that misrepresent someone's identity, will not be tolerated. We reserve the right to delete any comments in violation or to close comment threads on articles.
Please e-mail online@dailynorthwestern.com to flag a comment or for more information.
Be the first to comment on this story